SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (4235)10/22/1997 6:49:00 PM
From: Robert K.  Read Replies (1) | Respond to of 17367
 
I think they have had a lot of back and forth discussions about trial design. I guess they have the ok, just dotting the I's now.
P3 should start prior to Vienna shock forum. best estimate is about
end oct/ or start nov. Trauma could be more targeted which might lower potential market, but if meningo is strong, then what they target might not matter a whole lot to the doctors prescribing. But thats down the road.



To: aknahow who wrote (4235)10/22/1997 10:23:00 PM
From: Andrew H  Respond to of 17367
 
>> it is believed that PIII Trauma trials will be given go ahead by FDA shortly after Nov presentation in Vienna. Or at least that what my mother said.<g> Figure you don't need explanation, but not sure.<<

Thanks, George. If your mother said it, no, I don't need an explanation. However, if you said it, I do. (:>)

Actually, its quite clear.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News